Have any questions? 706-721-6582 or cts@augusta.edu
- CA 209-77T A Phase 3, Randomized, Double-blind Study of Neoadjuvant Chemotherapy plus Nivolumab versu Neoadjuvant Chemotherapy plus Placebo, followed by Surgical Resection and Adjuvant Treatment with Nivolumab or Placebo for Participants with Resectable Stage II-IIIB Non-small Cell Lung Cancer (Checkmate 77T, CHECKpoint pathway and nivoluMAb clinical Trial Evolution 77T)
Clinical Trial
CA 209-77T A Phase 3, Randomized, Double-blind Study of Neoadjuvant Chemotherapy plus Nivolumab versu Neoadjuvant Chemotherapy plus Placebo, followed by Surgical Resection and Adjuvant Treatment with Nivolumab or Placebo for Participants with Resectable Stage II-IIIB Non-small Cell Lung Cancer (Checkmate 77T, CHECKpoint pathway and nivoluMAb clinical Trial Evolution 77T)
The purpose of this study is to see if treatment with nivolumab in combination with chemotherapy before the surgery followed by treatment with nivolumab after the surgery is better at preventing the return of the cancer and better at improving survival when compared to treatment with chemotherapy alone. This study will also test the safety, and tolerability of nivolumab combined with chemotherapy in patients with resectable Non-Small Cell Lung Cancer.
Eligibility Criteria
- Eligibility Criteria: Subjects with suspected or histologically confirmed Stage IIA to IIIB (T3N2) NSCLC with disease that is considered resectable. No brain metastises. A male or female at least 18 years of age or older. Subjects with known ALK mutations are excluded
RESEARCH. INNOVATION. DISCOVERY.